Lung Cancer RNA Panel (ALK, RET, ROS1 & MET Mutations)
Available Now
Product Name/Description |
No. of Reactions*
|
Product Code |
---|---|---|
Lung Cancer RNA Panel (ROS1, RET, ALK & MET Mutations) |
48
|
LUNG-RT48 |
* Includes all controls
Fusion Genes in Lung Cancer
Non–small-cell lung cancer (NSCLC) is frequently associated with aberrant tyrosine kinase activity that abnormally activates downstream signaling pathways. Aberrant tyrosine kinase activity has been linked to chromosomal translocations involving ALK, ROS1 and RET which are found in 3-7%, ~2%, and ~1% of patients with NSCLC, respectively. The presence of ALK and ROS1 fusion genes predicts response to several recently approved tyrosine kinase inhibitors (TKIs) (crizotinib, ceritinib and alectinib). Lung cancer patients harboring RET fusion genes may be candidates for RET inhibitors (vandetanib and cabozantinib) which are approved for thyroid cancer treatment.
Kit Features
The Lung Cancer RNA Panel provides reagents for detecting ALK, ROS1, and RET fusion genes as well as MET exon 14 skipping mutations in human lung RNA.
The one-step assay combines first-strand cDNA synthesis (reverse transcription) and subsequent amplification of mutant and reference genes, minimizing hands-on time and reducing the risk of introducing contaminants during the workflow. The kit detects a total of 47 variants (see tables below) in 8 reactions.
This kit is compatible with various sample types and can be used to detect mutations in RNA isolated from fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples.
ALK Fusion Gene Variant | Chromosomal Translocation |
---|---|
EML4-ALK | E13;A20 |
E20;A20 | |
E20;ins18A20 | |
E6;A20 | |
E6ins33;A20 | |
E6;ins18A20 | |
E14ins11;del49A20 | |
E2;A20 | |
E2;ins117A20 | |
E13;ins69A20 | |
E14;del14A20 | |
E14;del36A20 | |
E17;ins30A20 | |
E17ins61;ins34A20 | |
E17del58ins39;A20 | |
E17ins65;A20 | |
E17;ins68A20 | |
E15del60;del71A20 | |
E18;A20 | |
E3;ins53A20 | |
E6;A19 |
ROS1 Fusion Gene Variant | Chromosomal Translocation |
---|---|
SLC34A2-ROS1 | S4;R32 |
S13del;R32 | |
S4;R34 | |
S13del;R34 | |
CD74-ROS1 | C6;R32 |
C7;R32 | |
C6;R34 | |
SDC4-ROS1 | S2;R32 |
S4;R32 | |
S4;R34 | |
EZR-ROS1 | E10;R34 |
LRIG3-ROS1 | L16;R35 |
TPM3-ROS1 | T8;R35 |
GOPC-ROS1 | G7;R35 |
G4;R36 |
RET Fusion Gene Variant | Chromosomal Translocation |
---|---|
KIF5B-RET | K15;R12 |
K16;R12 | |
K22;R12 | |
K23;R12 | |
K24;R8 | |
K24;R11 | |
K15;R11 | |
CCDC6-RET | C1;R12 |
NCOA4-RET | N6;R12 |
TRIM33-RET | T14;R12 |
Gene | Mutation |
---|---|
MET | Exon 14 skipping |
Equipment & Materials
The Lung Cancer RNA Panel requires a real-time PCR instrument capable of detecting FAM, VIC and CY5 fluorescent probes. This kit includes primer/probe mix for detection of all variants mentioned above, one-step enzyme mix for cDNA synthesis and PCR detection, as well as validated controls. Columns and reagents for RNA isolation are not included.
Intended Use
USA:
EntroGen’s Lung Fusion Gene Panel is available for research use only (RUO). Not for use in diagnostic procedures.
Europe:
EntroGen’s Lung Fusion Gene Panel is available for research (RUO) and diagnostic (CE-IVD) purposes.
Overview
- Works with FFPE and fresh frozen samples.
- One step RT-qPCR.
- Simple setup and interpretation.
- Includes internal control.